Offers Updates on AIkido Pharma Share Repurchase Program


New York, September 30, 2022 /PRNewswire/ — AIkido Pharma Inc. (NASDAQ:AIKI) (“AIkido” or the “Firm”) right this moment offered an replace on $3 million Share Repurchase Program (“Share Repurchase Program”) licensed by the Firm’s Board of Administrators 21 January 2022,

As a part of the share repurchase programme, the corporate has repurchased 303,886 widespread shares in the course of the interval. 21 January 2022 as much as and together with September 29, 2022, The value per share restrict for the repurchased shares was $5.34 To $6.97,

Further shares might every so often be exchanged in open market transactions, or by different means pursuant to Rule 10b5-1 of the Securities Alternate Act 1934 (“The Alternate Act”), and Guidelines 10b -18 of the Alternate Act. Timing, variety of shares repurchased and costs paid for inventory below this program rely on regular enterprise and market situations in addition to company and regulatory limits, together with blackout interval restrictions.

About Aikido Pharma Inc.

AIkido Pharma Inc. was based in 1967 and is a biotechnology firm with a various portfolio of small-molecule anticancer and antiviral therapeutics. The corporate’s platform incorporates patented know-how from main universities and researchers, and we’re at present within the technique of growing an progressive therapeutic drug platform by way of robust partnerships with world-renowned educational establishments, together with College of Texas at Austin And College of Maryland in Baltimore, Our numerous pipeline of therapeutics consists of therapies for pancreatic most cancers, prostate most cancers. We’re regularly looking for to develop our pipeline to deal with unmet medical wants in oncology. The corporate can be growing a broad-spectrum antiviral platform that may doubtlessly inhibit the replication of a number of viruses, together with Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

forward-looking statements

Sure statements on this press launch represent “forward-looking statements” throughout the that means of federal securities legal guidelines. phrases equivalent to “may,” “may,” “will,” “ought to,” “imagine,” “count on,” “estimate,” “estimate,” “proceed,” “predict,” “forecast, “Undertaking,” “plan,” “intent” or comparable expressions, or statements about intention, perception, or present expectations, are forward-looking statements. Whereas the Firm believes that these forward-looking statements are affordable, undue reliance needs to be positioned on any forward-looking statements which might be based mostly on data obtainable to us on the date of this launch. These forward-looking statements are based mostly on present estimates and assumptions and are topic to numerous dangers and uncertainties, together with however not restricted to danger components associated to its enterprise, contained herein, as set out within the firm’s filings with the SEC. Thus, precise outcomes might differ materially. The corporate expressly disclaims any obligation to replace or change the statements for brand spanking new data, future occasions or in any other case, besides as required by regulation.


Investor Relations:

Hayden IR
Brett Maas, Managing Associate
Cellphone: (646) 536-7331
E mail:

Aikido Pharma Inc.:

Cellphone: 212-745-1373
E mail: Investor

Decision To obtain multimedia, go to the unique content material:

Supply Aikido Pharma Inc.


Supply hyperlink

Top Wool Lc

Top Wool Lc